Clinical Validation of the CureMatch Approach
CureMatch® CTO is co-author in Cancer Discovery Journal article showing computational modeling of drug resistance caused by gene mutations advances personalized cancer medicine. SAN DIEGO, CA – January 25, 2018: Igor F. Tsigelny, Ph.D., Co-founder and Chief Technology Officer at CureMatch and research professor at University of California, San Diego, is a co-author of “Genomic landscape […]
A study of 136 patients with advanced cancers performed by UCSD oncologist and CureMatch co-founder Dr. Razelle Kurzrock and colleagues suggested that combination therapy may be more efficacious than single-drug therapy.
A study performed by UCSD oncologist and CureMatch co-founder Dr. Razelle Kurzrock and colleagues looked at 57 breast cancer patients using next-generation sequencing (NGS), and found that no two were the same. A total of 216 somatic
A multi-year study was performed by UCSD oncologist and CureMatch co-founder Dr. Razelle Kurzrock and colleagues, and looked at 291 patients with advanced cancers, who had received either the standard of care (n = 116) or personalized cancer therapy (n = 175). Patients treated using the standard of care, which was based on their type of cancer, had […]
A personalized approach to cancer therapy leads to improved outcomes in a wide variety of cancers. Personalized cancer therapy correlated with higher response rates, prolonged progression-free survival, and overall survival of cancer patients when compared to non-personalized approaches, in a meta-analysis of more than 330,000 patients enrolled in clinical trials. Schwaederle M, Zhao M, […]
